• 1. Enabling stable MnO2 matrix for aqueous zinc-ion battery cathodes?
  Yiding Jiao,Liqun Kang,Jasper Berry-Gair,Kit McColl,Jianwei Li,Haobo Dong,Hao Jiang,Ryan Wang,Furio Corà,Dan J. L. Brett,Ivan P. Parkin J. Mater. Chem. A, 2020,8, 22075-22082
• 2. Establishing plasmon contribution to chemical reactions: alkoxyamines as a thermal probe?
  Olga Guselnikova,Gérard Audran,Jean-Patrick Joly,Andrii Trelin,Evgeny V. Tretyakov,Vaclav Svorcik,Oleksiy Lyutakov,Sylvain R. A. Marque Chem. Sci., 2021,12, 4154-4161
• 3. Examination of the hydrogen-bonding networks in small water clusters (n = 2–5, 13, 17) using absolutely localized molecular orbital energy decomposition analysis?
  Erika A. Cobar,Paul R. Horn,Robert G. Bergman,Martin Head-Gordon Phys. Chem. Chem. Phys., 2012,14, 15328-15339
• 4. Emerging investigator series: first-principles and thermodynamics comparison of compositionally-tuned delafossites: cation release from the (001) surface of complex metal oxides?
  Joseph W. Bennett,Diamond T. Jones,Blake G. Hudson,Joshua Melendez-Rivera,Robert J. Hamers,Sara E. Mason Environ. Sci.: Nano, 2020,7, 1642-1651
• 5. Fatty acid positional distribution in colostrum and mature milk of women living in Inner Mongolia, North Jiangsu and Guangxi of China?
  Long Deng,Qian Zou,Biao Liu,Wenhui Ye,Chengfei Zhuo,Li Chen,Ze-Yuan Deng,Ya-Wei Fan,Jing Li Food Funct., 2018,9, 4234-4245

• Solvents and Organic Chemicals Organic Compounds Benzenoids Phenol ethers Phenol ethers
• Solvents and Organic Chemicals Organic Compounds Benzenoids Phenol ethers

Introduction to 3-Bromo-4-(2-methoxyethoxy)benzaldehyde (CAS No. 915369-06-1)

3-Bromo-4-(2-methoxyethoxy)benzaldehyde, identified by the Chemical Abstracts Service Number (CAS No.) 915369-06-1, is a specialized organic compound that has garnered significant attention in the field of pharmaceutical chemistry and synthetic biology. This aromatic aldehyde features a bromine substituent at the third position and an ethoxy group linked to the second carbon of an methoxyethoxy side chain, making it a versatile intermediate in the synthesis of more complex molecules.

The structural uniqueness of 3-Bromo-4-(2-methoxyethoxy)benzaldehyde lies in its combination of a reactive aldehyde functional group and halogenated aromatic ring, which facilitates various chemical transformations. The presence of both bromine and methoxyethoxy groups enhances its utility as a building block in medicinal chemistry, enabling the construction of diverse pharmacophores. Such structural features are particularly valuable in designing molecules with tailored biological activities.

In recent years, there has been growing interest in exploring the potential of 3-Bromo-4-(2-methoxyethoxy)benzaldehyde as a precursor in drug discovery initiatives. Its reactivity allows for facile modifications through cross-coupling reactions, such as Suzuki-Miyaura or Buchwald-Hartwig couplings, which are pivotal in generating biaryl structures prevalent in many therapeutic agents. Additionally, the aldehyde functionality can participate in condensation reactions to form Schiff bases or undergo oxidation to yield carboxylic acids, further expanding its synthetic utility.

One of the most compelling applications of 3-Bromo-4-(2-methoxyethoxy)benzaldehyde is in the development of novel antimicrobial agents. The bromine atom serves as a handle for further derivatization, allowing chemists to introduce additional substituents that modulate binding interactions with biological targets. Recent studies have highlighted its role in synthesizing analogs with enhanced activity against resistant bacterial strains, underscoring its importance in addressing emerging infectious diseases.

The methoxyethoxy side chain contributes to the lipophilicity and solubility profile of 3-Bromo-4-(2-methoxyethoxy)benzaldehyde, making it an attractive candidate for oral or parenteral administration. This characteristic is particularly relevant in oncology research, where optimizing pharmacokinetic properties is critical for therapeutic efficacy. Researchers have leveraged this compound to develop kinase inhibitors, which are essential in targeting aberrant signaling pathways in cancer cells.

Another area where 3-Bromo-4-(2-methoxyethoxy)benzaldehyde has shown promise is in neurodegenerative disease research. The compound’s ability to engage with specific enzymatic systems has led to the synthesis of potential neuroprotective agents. Preliminary findings suggest that derivatives derived from this scaffold may interact with amyloid-beta plaques or tau protein aggregates, offering new avenues for treating conditions such as Alzheimer’s disease and Parkinson’s disease.

The synthetic pathways involving 3-Bromo-4-(2-methoxyethoxy)benzaldehyde have also been refined through modern catalytic techniques. Transition-metal-catalyzed reactions have enabled more efficient and selective transformations, reducing byproduct formation and improving yields. These advancements are crucial for large-scale production and ensure that researchers can access sufficient quantities of this valuable intermediate without compromising purity or cost-effectiveness.

From a computational chemistry perspective, virtual screening methods have been employed to identify novel derivatives of 3-Bromo-4-(2-methoxyethoxy)benzaldehyde with enhanced binding affinity to biological targets. Machine learning models trained on large datasets have predicted optimal substitution patterns, guiding experimental design and accelerating the discovery process. This interdisciplinary approach underscores the importance of integrating computational tools with traditional synthetic methodologies.

The environmental impact of utilizing 3-Bromo-4-(2-methoxyethoxy)benzaldehyde has also been considered in recent research. Efforts have been made to develop greener synthetic routes that minimize waste generation and reduce reliance on hazardous reagents. Such sustainable practices are increasingly vital as pharmaceutical industries strive to align with global environmental standards while maintaining high-quality output.

In conclusion, 3-Bromo-4-(2-methoxyethoxy)benzaldehyde (CAS No. 915369-06-1) represents a cornerstone compound in modern medicinal chemistry. Its unique structural attributes enable diverse synthetic applications, making it indispensable in drug discovery programs targeting infections, cancer, and neurodegenerative disorders. As research continues to evolve, this compound will undoubtedly play an even more pivotal role in shaping the future of therapeutic innovation.

• 191602-84-3(3-Bromo-4-isopropoxybenzaldehyde)
• 90109-65-2(3-Bromo-4-ethoxy-5-methoxybenzaldehyde)
• 34841-06-0(3-Bromo-4-methoxybenzaldehyde)
• 108373-05-3(3-Bromo-4-ethoxybenzaldehyde)
• 724746-23-0(3-Bromo-4-(prop-2-en-1-yloxy)benzaldehyde)
• 69455-12-5(4-(Benzyloxy)-3-bromobenzaldehyde)
• 81805-97-2(3-Bromo-5-ethoxy-4-methoxybenzaldehyde)
• 865138-64-3(3-Bromo-4-propoxybenzaldehyde)
• 860003-88-9(8-Bromo-2,3-dihydrobenzob1,4dioxine-6-carbaldehyde)
• 90109-64-1(3-Bromo-4,5-diethoxybenzaldehyde)